230 related articles for article (PubMed ID: 8336939)
1. Expression and amplification of cyclin genes in human breast cancer.
Buckley MF; Sweeney KJ; Hamilton JA; Sini RL; Manning DL; Nicholson RI; deFazio A; Watts CK; Musgrove EA; Sutherland RL
Oncogene; 1993 Aug; 8(8):2127-33. PubMed ID: 8336939
[TBL] [Abstract][Full Text] [Related]
2. Chromosomal and extrachromosomal instability of the cyclin D2 gene is induced by Myc overexpression.
Mai S; Hanley-Hyde J; Rainey GJ; Kuschak TI; Paul JT; Littlewood TD; Mischak H; Stevens LM; Henderson DW; Mushinski JF
Neoplasia; 1999 Aug; 1(3):241-52. PubMed ID: 10935479
[TBL] [Abstract][Full Text] [Related]
3. The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer.
Gomes I; Abreu C; Costa L; Casimiro S
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835528
[TBL] [Abstract][Full Text] [Related]
4. Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer.
Fradley MG; Nguyen NHK; Madnick D; Chen Y; DeMichele A; Makhlin I; Dent S; Lefebvre B; Carver J; Upshaw JN; DeRemer D; Ky B; Guha A; Gong Y
J Am Heart Assoc; 2023 Jun; 12(12):e029361. PubMed ID: 37301767
[TBL] [Abstract][Full Text] [Related]
5. Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation.
Wang J; Su W; Zhang T; Zhang S; Lei H; Ma F; Shi M; Shi W; Xie X; Di C
Cell Death Dis; 2023 Apr; 14(4):244. PubMed ID: 37024471
[TBL] [Abstract][Full Text] [Related]
6. Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.
Clark AS; Hong F; Finn RS; DeMichele AM; Mitchell EP; Zwiebel J; Arnaldez FI; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Copur MS; Kasbari SS; Thind R; Conley BA; Arteaga CL; O'Dwyer PJ; Harris LN; Chen AP; Flaherty KT
Clin Cancer Res; 2023 Apr; 29(8):1477-1483. PubMed ID: 36853016
[TBL] [Abstract][Full Text] [Related]
7. Emerging functions of C/EBPβ in breast cancer.
Matherne MG; Phillips ES; Embrey SJ; Burke CM; Machado HL
Front Oncol; 2023; 13():1111522. PubMed ID: 36761942
[TBL] [Abstract][Full Text] [Related]
8. A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming.
Yousefi H; Khosla M; Lauterboeck L; Okpechi SC; Worthylake D; Garai J; Zabaleta J; Guidry J; Zarandi MA; Wyczechowska D; Jayawickramarajah J; Yang Q; Kissil J; Alahari SK
Oncogene; 2022 Nov; 41(47):5076-5091. PubMed ID: 36243802
[TBL] [Abstract][Full Text] [Related]
9. CDK4: a master regulator of the cell cycle and its role in cancer.
Baker SJ; Poulikakos PI; Irie HY; Parekh S; Reddy EP
Genes Cancer; 2022; 13():21-45. PubMed ID: 36051751
[TBL] [Abstract][Full Text] [Related]
10. Induced mammary cancer in rat models: pathogenesis, genetics, and relevance to female breast cancer.
Miller JL; Bartlett AP; Harman RM; Majhi PD; Jerry DJ; Van de Walle GR
J Mammary Gland Biol Neoplasia; 2022 Jun; 27(2):185-210. PubMed ID: 35904679
[TBL] [Abstract][Full Text] [Related]
11. Kindlin-2 promotes Src-mediated tyrosine phosphorylation of androgen receptor and contributes to breast cancer progression.
Ma L; Tian Y; Qian T; Li W; Liu C; Chu B; Kong Q; Cai R; Bai P; Ma L; Deng Y; Tian R; Wu C; Sun Y
Cell Death Dis; 2022 May; 13(5):482. PubMed ID: 35595729
[TBL] [Abstract][Full Text] [Related]
12. Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors.
West MT; Kartika T; Paquin AR; Liederbauer E; Zheng TJ; Lane L; Thein K; Shatzel JJ
Curr Probl Cancer; 2022 Apr; 46(2):100832. PubMed ID: 35034766
[TBL] [Abstract][Full Text] [Related]
13. Hypophosphorylated pRb knock-in mice exhibit hallmarks of aging and vitamin C-preventable diabetes.
Jiang Z; Li H; Schroer SA; Voisin V; Ju Y; Pacal M; Erdmann N; Shi W; Chung PED; Deng T; Chen NJ; Ciavarra G; Datti A; Mak TW; Harrington L; Dick FA; Bader GD; Bremner R; Woo M; Zacksenhaus E
EMBO J; 2022 Feb; 41(4):e106825. PubMed ID: 35023164
[TBL] [Abstract][Full Text] [Related]
14. Implications of TGFβ Signaling and CDK Inhibition for the Treatment of Breast Cancer.
Decker JT; Ma JA; Shea LD; Jeruss JS
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771508
[TBL] [Abstract][Full Text] [Related]
15. On the Rise of Cyclin-Dependent Kinase Inhibitors in Breast Cancer:
Makhlin I; DeMichele A
Breast Cancer Manag; 2020 Jun; 9(2):. PubMed ID: 34475968
[No Abstract] [Full Text] [Related]
16. Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis.
Kashyap D; Garg VK; Sandberg EN; Goel N; Bishayee A
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33920506
[TBL] [Abstract][Full Text] [Related]
17. Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays.
Sadeghi F; Asgari M; Matloubi M; Ranjbar M; Karkhaneh Yousefi N; Azari T; Zaki-Dizaji M
Biol Proced Online; 2020; 22():23. PubMed ID: 33013205
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of miR-34a Effect on CCND1 mRNA Level and Sensitization of Breast Cancer Cell Lines to Paclitaxel.
Irani S; Paknejad M; Soleimani M; Azam S
Iran Biomed J; 2020 Nov; 24(6):361-9. PubMed ID: 32660221
[TBL] [Abstract][Full Text] [Related]
19. Multiple Functions of Fubp1 in Cell Cycle Progression and Cell Survival.
Kang M; Kim HJ; Kim TJ; Byun JS; Lee JH; Lee DH; Kim W; Kim DY
Cells; 2020 May; 9(6):. PubMed ID: 32481602
[TBL] [Abstract][Full Text] [Related]
20. Cyclin D1 overexpression in Algerian breast cancer women: correlation with CCND1 amplification and clinicopathological parameters.
Mohammedi L; Doula FD; Mesli F; Senhadji R
Afr Health Sci; 2019 Jun; 19(2):2140-2146. PubMed ID: 31656498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
